**Wegovy News Update: Oral Pill Approval, Patent Wins, Safety Shifts & Rising Competition from Lilly**
Wegovy is making headlines again — and this episode breaks down everything you need to know. From the EU's landmark approval of the first-ever oral GLP-1 pill for obesity to Novo Nordisk's $149/month U.S. pricing strategy, we cover the biggest shifts reshaping the weight loss drug market.
**In this episode, we explore:**
✅ **Oral Wegovy expansion** — European Commission approval, U.S. launch pricing, and a new high-strength injection pen
✅ **Sales performance & investor reaction** — Why softer-than-expected pill sales are pressuring Novo Nordisk's stock despite 5 million+ prescriptions in six months
✅ **Legal battles** — Novo Nordisk's court win against compounded semaglutide nasal spray in the Netherlands
✅ **Safety updates** — New research linking Wegovy to rare eye stroke risk, plus the FDA's decision to remove suicidal ideation warnings from GLP-1 labels
✅ **Competitive pressure** — How Eli Lilly's tirzepatide outperformed semaglutide in the SURMOUNT-5 head-to-head trial
✅ **What's next** — Novo Nordisk's pipeline bets on oral amycretin, combination therapies, and long-acting semaglutide implants
✅ **Access & distribution** — Amazon Pharmacy's new GLP-1 delivery program for Medicare patients
Whether you're tracking Novo Nordisk stock, researching GLP-1 weight loss medications, or just trying to understand how the obesity drug market is evolving, this episode delivers a clear, fast-paced rundown of the latest Wegovy news — separating real signal from market noise.
**Perfect for:** investors following pharma stocks, healthcare professionals, patients on GLP-1 medications, and anyone following the semaglutide vs. tirzepatide competition.
🎧 Tune in now, and subscribe for weekly updates on the fast-moving world of obesity drugs and weight loss medication news.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
